← Back to headlines
RBC Reiterates Outperform Rating for Merck (MRK) Amid Investor Concerns
RBC Capital Markets has reiterated its 'Outperform' rating for Merck (MRK), acknowledging investor concerns regarding a 'modest premium' but maintaining a positive outlook for the pharmaceutical company.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
